Floatz logo

(+)-VINCRISTINE

T Cell Lymphoma

Dizal PharmaceuticalsSmall moleculePhase 3Active
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
60/ 100
Competitive Position
89/ 100

Competitive context

9 Active assets in the T Cell Lymphoma cohort.

Asset / SponsorPhaseRating
cd19-ucart
Beijing GoBroad Hospital
Phase 1/2B
Tenalisib
Rhizen Pharmaceuticals SA
Phase 1/2B
Fostamatinib Disodium
Rigel Pharmaceuticals
Phase 2B
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
Won Seog Kim
Phase 1/2CCC
MOGAMULIZUMAB
Yale University
Phase 2CCC

View all 20 →

Same molecule, other indications

(+)-VINCRISTINE is also rated in:

anaplastic large cell lymphomaDormant
BBB
Indicative ·
78 / 100
View asset →
mycosis fungoidesDormant
BBB
Indicative ·
78 / 100
View asset →
adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →